GELS$0.4968+1.47%
Gelteq Ltd
Sector: Pharmaceutical PreparationsIndustry: Drug Manufacturers - Specialty & GenericCountry: AUExchange: Nasdaq
Mkt Cap:$5.56M
Float & O/S:
Inst Own:
DilutionScan read 15 of Gelteq Ltd's SEC filings and found 1 warrant series, 9 convertibles, 1 equity line, 1 S-1 registration and 4 completed offerings on file for GELS. The latest dilution event on file is an offering on Jun 26, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
GELS
Going-concern warning and exhausted cash
Snapshot
Gelteq is a micro-cap biotech in a severe liquidity crisis. It generated just $116K in FY 2025 revenue against a $4.7M net loss, burning through $4.3M in free cash flow.
What's Happening Right Now
- : The company filed its earnings with a six-month delay, reporting a working capital deficit and cash under $10,000, with auditors preparing the statements on a going concern basis.
- : Gelteq announced that human clinical trials are set to begin in July 2026 and secured a $3.5 million strategic debt facility to fund operations.
- : Management called a special shareholder meeting to approve issuing shares above the Nasdaq 19.9% limit to facilitate the conversion of recent debt financing.
